Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study

被引：0
|
作者：
Meghan E. Jones
Jeffrey S. Andrews
Douglas E. Faries
John Landry
Jenny Xu
Holland C. Detke
Rashna Chhabra-Khanna
David P. McDonnell
机构：
[1] Eli Lilly and Company,
[2] Eli Lilly Canada,undefined
[3] Inc.,undefined
[4] MacroStat (China) Clinical Research Co.,undefined
[5] Ltd.,undefined
[6] Lilly UK,undefined
[7] Eli Lilly and Company,undefined
来源：
BMC Psychiatry | / 15卷
关键词：
Olanzapine; Long-acting injection; Schizophrenia; Antipsychotics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study
    Jones, Meghan E.
    Andrews, Jeffrey S.
    Faries, Douglas E.
    Landry, John
    Xu, Jenny
    Detke, Holland C.
    Chhabra-Khanna, Rashna
    McDonnell, David P.
    BMC PSYCHIATRY, 2015, 15
  • [2] Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study
    Llorca, Pierre-Michel
    Bobes, Julio
    Fleischhacker, W. Wolfgang
    Heres, Stephan
    Moore, Nicholas
    Bent-Ennakhil, Nawal
    Sapin, Christophe
    Loze, Jean-Yves
    Nylander, Anna-Greta
    Patel, Maxine X.
    EUROPEAN PSYCHIATRY, 2018, 52 : 85 - 94
  • [3] Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study
    Meyers, Kristin J.
    Upadhyaya, Himanshu P.
    Landry, John L.
    Chhabra-Khanna, Rashna
    Falk, Deborah M.
    Rao, Balasubramanya Seetharama
    Jones, Meghan E.
    BJPSYCH OPEN, 2017, 3 (04): : 186 - 192
  • [4] LONG-ACTING INJECTABLE RISPERIDONE AND ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA - A PROSPECTIVE ONE-YEAR NON-INTERVENTIONAL STUDY (INORS)
    Schreiner, A.
    Svensson, A.
    Wapenaar, R.
    Cherubin, P.
    Princet, P.
    Serazetdinova, L.
    Starostina, N.
    Zink, M.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [5] Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS)
    Schreiner, Andreas
    Svensson, Anders
    Wapenaar, Robert
    Cherubin, Pierre
    Princet, Patricia
    Serazetdinova, Larisa
    Zink, Mathias
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2014, 15 (07): : 534 - 545
  • [6] Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
    Peuskens, Joseph
    Porsdal, Vibeke
    Pecenak, Jan
    Handest, Peter
    D'yachkova, Yulia
    Brousil, Radim
    Deberdt, Walter
    BMC PSYCHIATRY, 2012, 12
  • [7] Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
    Joseph Peuskens
    Vibeke Porsdal
    Jan Pecenak
    Peter Handest
    Yulia D'yachkova
    Radim Brousil
    Walter Deberdt
    BMC Psychiatry, 12
  • [8] Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia - a 1-year non-interventional study
    Schreiner, A.
    Svensson, A.
    Wapenaar, R.
    Cherubin, P.
    Princet, P.
    Serazetdinova, L.
    Starostina, N.
    Zink, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S240 - S240
  • [9] NATURALISTIC OBSERVATIONAL STUDY OF PATIENTS RECEIVING RISPERIDONE LONG-ACTING INJECTION (RLAI)
    Gupta, N.
    Riley, C.
    Agell, I.
    EUROPEAN PSYCHIATRY, 2009, 24
  • [10] Safety and efficacy of olanzapine long-acting injection for up to 6 years in patients with schizophrenia or schizoaffective disorder
    McDonnell, D. P.
    Detke, H. C.
    Choukour, M.
    Landry, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S319 - S320
12345